Smalley KSM - Search Results

1

Noncanonical EphA2 Signaling Is a Driver of Tumor-Endothelial Cell Interactions and Metastatic Dissemination in BRAF Inhibitor‒Resistant Melanoma.

Zhang C, Smalley I, Emmons MF, Sharma R, Izumi V, Messina J, Koomen JM, Pasquale EB, Forsyth PA, Smalley KSM. Zhang C, et al. Among authors: smalley ksm, smalley i. J Invest Dermatol. 2021 Apr;141(4):840-851.e4. doi: 10.1016/j.jid.2020.08.012. Epub 2020 Sep 2. J Invest Dermatol. 2021. PMID: 32890629 Free PMC article.

2

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

Smalley KS, Flaherty KT. Smalley KS, et al. Br J Cancer. 2009 Feb 10;100(3):431-5. doi: 10.1038/sj.bjc.6604891. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156138 Free PMC article. Review.

3

Genetic subgrouping of melanoma reveals new opportunities for targeted therapy.

Smalley KS, Nathanson KL, Flaherty KT. Smalley KS, et al. Cancer Res. 2009 Apr 15;69(8):3241-4. doi: 10.1158/0008-5472.CAN-08-4305. Epub 2009 Apr 7. Cancer Res. 2009. PMID: 19351826 Review.

4

Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Smalley KS. Smalley KS. J Invest Dermatol. 2010 Jan;130(1):28-37. doi: 10.1038/jid.2009.177. J Invest Dermatol. 2010. PMID: 19571822 Free article.

5

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Sondak VK, Smalley K. Sondak VK, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x. Pigment Cell Melanoma Res. 2009. PMID: 19624312 No abstract available.

6

Methods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.

Fang B, Haura EB, Smalley KS, Eschrich SA, Koomen JM. Fang B, et al. Biochem Pharmacol. 2010 Sep 1;80(5):739-47. doi: 10.1016/j.bcp.2010.03.027. Epub 2010 Mar 31. Biochem Pharmacol. 2010. PMID: 20361944 Free PMC article. Review.

7

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Paraiso KH, et al. Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714. Br J Cancer. 2010. PMID: 20531415 Free PMC article.

8

Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Paraiso KH, Van Der Kooi K, Messina JL, Smalley KS. Paraiso KH, et al. Methods Enzymol. 2010;484:549-67. doi: 10.1016/B978-0-12-381298-8.00027-7. Methods Enzymol. 2010. PMID: 21036250 Free PMC article.

9

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. Paraiso KH, et al. Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11. Cancer Res. 2011. PMID: 21317224 Free PMC article.

10

Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.

Koomen JM, Smalley KS. Koomen JM, et al. Oncotarget. 2011 Apr;2(4):329-35. doi: 10.18632/oncotarget.263. Oncotarget. 2011. PMID: 21505227 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

201 results

Search Page

Filters